US Patent

US8158601 — Lipid formulation

Method of Use · Assigned to Alnylam Pharmaceuticals Inc · Expires 2030-11-10 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a cationic lipid formulation and corresponding methods of use, assigned to Alnylam Pharmaceuticals Inc.

USPTO Abstract

The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2378 — Onpattro

Patent Metadata

Patent number
US8158601
Jurisdiction
US
Classification
Method of Use
Expires
2030-11-10
Drug substance claim
No
Drug product claim
Yes
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.